Watch AVBP. Know when insiders buy.
One email the day a filing lands. Free.
AVBP
ArriVent BioPharma, Inc.
30.95
−0.08 −0.26%
USD · close Sep 4
A free account adds a watchlist, alerts when insiders, Congress or short sellers move on your tickers, and a morning brief. Sign up
Work order
45
WATCH · shorts 45
Insiders, 90 days
0
no open-market filings in 90 days
Congress, 90 days
0 / 0
no disclosures naming it
Big money
0 / 15
none of the tracked funds disclose it
Calls on record
0
nobody we score has called it yet
MKT CAP $1.5BP/E —DIV YIELD —FCF YIELD —REV TTM —NET INCOME −$163.7MNET CASH —52W 17.17 – 34.74SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q2 2026 · Jun 30 | — | — | — | −$52.7M | −$49.9M | — | -1.05 | −$39.6M | — | — | Aug 12 |
| Q1 2026 · Mar 31 | — | — | — | −$46.1M | −$43.3M | — | -0.96 | −$41.9M | — | — | Aug 12 |
| Q4 2025 · Dec 31derived | — | — | — | −$38.8M | −$35.5M | — | -0.78 | −$30.7M | — | — | Mar 5 |
| Q3 2025 · Sep 30 | — | — | — | −$38.3M | −$35M | — | -0.83 | −$35.8M | — | — | Nov 10 |
| Q2 2025 · Jun 30 | — | — | — | −$33.6M | −$31.4M | — | -0.90 | −$26.1M | — | — | Aug 12 |
| Q1 2025 · Mar 31 | — | — | — | −$66.8M | −$64.4M | — | -1.90 | −$68M | — | — | Aug 12 |
| Q4 2024 · Dec 31derived | — | — | — | −$23.7M | −$20.6M | — | -0.61 | −$16.2M | — | — | Mar 5 |
| Q3 2024 · Sep 30 | — | — | — | −$24.2M | −$20.6M | — | -0.61 | −$16.3M | — | — | Nov 10 |
| Q2 2024 · Jun 30 | — | — | — | −$25.7M | −$21.9M | — | -0.65 | −$19.1M | — | — | Nov 10 |
| Q1 2024 · Mar 31 | — | — | — | −$20.7M | −$17.4M | — | -0.70 | −$18.6M | — | — | Nov 10 |
| Q4 2023 · Dec 31derived | — | — | — | −$23.1M | −$21.2M | — | -7.69 | −$14.9M | — | — | Mar 3 |
| Q3 2023 · Sep 30 | — | — | — | −$16.7M | −$14.4M | — | -5.52 | −$15.4M | — | — | Nov 14 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 · to Dec 31 | — | — | −$177.5M | −$166.3M | — | -4.32 | −$160.6M | — | — | — | — |
| FY2024 · to Dec 31 | — | — | −$94.3M | −$80.5M | — | -2.56 | −$70.2M | — | — | — | — |
| FY2023 · to Dec 31 | — | — | −$74.6M | −$69.3M | — | -32.38 | −$55.8M | — | — | — | — |
Every number comes from ArriVent BioPharma, Inc.'s own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.